Triple
T10291909
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | andexanet alfa |
E241384
|
entity |
| Predicate | developedBy |
P73
|
FINISHED |
| Object | Alexion Pharmaceuticals |
E505487
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Alexion Pharmaceuticals | Statement: [andexanet alfa, developedBy, Alexion Pharmaceuticals]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alexion Pharmaceuticals Context triple: [andexanet alfa, developedBy, Alexion Pharmaceuticals]
-
A.
Alexion Pharmaceuticals
chosen
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
B.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
-
C.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381aaafc08190af475ef58dc16aba |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d4d2d35f048190a215493acdf1f718 |
completed | April 7, 2026, 9:48 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d6f85dcbac8190a2ac66354010e328 |
completed | April 9, 2026, 12:52 a.m. |
Created at: April 6, 2026, 11:42 a.m.